Based on the poor overall outcome and significant toxicity of upfront chemotherapy in advanced non-small cell lung cancer, EGFR TKI therapy as front-line treatment has significant appeal for the appropriate patient. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.